NCT06152575

MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

RecruitingPHASE3INTERVENTIONAL

Trial Details

Start: 2024-02-08Est. Completion: 2026-08-30

Enrollment target: 492 participants

Locations

Infirmary Cancer Care, Mobile, Alabama, United States
Western Regional Medical Center, Inc. dba. City of Hope Phoenix, Goodyear, Arizona, United States
Beverly Hills Cancer Center, Beverly Hills, California, United States
Clovis Community Medical Center, Clovis, California, United States
Community Cancer Institute, Clovis, California, United States
Clinical Research Advisors (Encino Satellite Location), Encino, California, United States
University of California San Francisco, Fresno, California, United States
Community Regional Medical Center, Fresno, California, United States
Hoag Health Center Irvine, Irvine, California, United States
Hoag Hospital Irvine, Irvine, California, United States
Clinical Research Advisors (Korea Town Satellite Location), Los Angeles, California, United States
Clinical Research Advisors (West Hollywood Satellite Location), Los Angeles, California, United States
Valkyrie Clinical Trials, Los Angeles, California, United States
Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States

Multiple Myeloma

The primary purpose is to determine the safety and tolerability of belantamab mafodotin in combination with nirogacestat…

Boston, United StatesEst. completion Apr 17, 2025

Multiple MylomaNewly Diagnosed Multiple Myeloma (NDMM)

This is a single-arm, dose-escalation exploratory study evaluating the safety and efficacy of RN1201, a BCMA/CD19-target…

Suzhou, ChinaEst. completion Jan 1, 2027

MicrobiomeTrials does not provide medical advice. Always consult your doctor before joining a clinical trial.